Recruiting OBSERVATIONAL NCT05778253

The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC

Circulating Tumor DNA (ctDNA) Dynamic Monitoring Plus Artificial Intelligence (AI)-Based Pathology Predict the Efficacy of Chemoimmunotherapy in Resectable Lung Squamous Cell Carcinoma (LSCC)

Sponsor: Second Xiangya Hospital of Central South University

Conditions Lung Squamous Cell Carcinoma

Interventions WES and ctDNA detection

Updated 3 times since 2023 Last updated: Mar 18, 2023 Started: Mar 23, 2023 Primary completion: Sep 23, 2028 Completion: Sep 23, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Lung Squamous Cell Carcinoma, this trial is actively recruiting participants. The trial is conducted by Second Xiangya Hospital of Central South University and has accumulated 3 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Apr 2023 — Jul 2024 [monthly]

Recruiting

First recorded

Mar 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Second Xiangya Hospital of Central South University
Shanghai OrigiMed Co., Ltd.

Data source: Second Xiangya Hospital of Central South University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Changsha, China